Filter results

Clinical Studies


Contact Us for the Latest Status

  • MC198A, Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in The Treatment of B Cell Malignancies Rochester, Minn.

    The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients.

    The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood. In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer. The new modified T cells are called the IC19/1563 treatment. The dose of IC19/1563 will depend on when the patient is enrolled on to the study.


Closed for Enrollment